Literature DB >> 20374001

A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.

Lanying Du1, Guangyu Zhao, Chris C S Chan, Lin Li, Yuxian He, Yusen Zhou, Bo-Jian Zheng, Shibo Jiang.   

Abstract

Development of vaccines is essential for the prevention of future recurrences of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318-536) RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded, being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20374001      PMCID: PMC2883479          DOI: 10.1089/vim.2009.0090

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  60 in total

1.  Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Authors:  Zhiwei Chen; Linqi Zhang; Chuan Qin; Lei Ba; Christopher E Yi; Fengwen Zhang; Qiang Wei; Tian He; Wenjie Yu; Jian Yu; Hong Gao; Xinming Tu; Agegnehu Gettie; Michael Farzan; Kwok-Yung Yuen; David D Ho
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.

Authors:  Kanta Subbarao; Josephine McAuliffe; Leatrice Vogel; Gary Fahle; Steven Fischer; Kathleen Tatti; Michelle Packard; Wun-Ju Shieh; Sherif Zaki; Brian Murphy
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.

Authors:  Y Guan; B J Zheng; Y Q He; X L Liu; Z X Zhuang; C L Cheung; S W Luo; P H Li; L J Zhang; Y J Guan; K M Butt; K L Wong; K W Chan; W Lim; K F Shortridge; K Y Yuen; J S M Peiris; L L M Poon
Journal:  Science       Date:  2003-09-04       Impact factor: 47.728

4.  Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.

Authors:  A Regnault; D Lankar; V Lacabanne; A Rodriguez; C Théry; M Rescigno; T Saito; S Verbeek; C Bonnerot; P Ricciardi-Castagnoli; S Amigorena
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

5.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.

Authors:  Zhi-Yong Yang; Wing-Pui Kong; Yue Huang; Anjeanette Roberts; Brian R Murphy; Kanta Subbarao; Gary J Nabel
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

Review 6.  Severe acute respiratory syndrome.

Authors:  J S M Peiris; Y Guan; K Y Yuen
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

7.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.

Authors:  J S M Peiris; C M Chu; V C C Cheng; K S Chan; I F N Hung; L L M Poon; K I Law; B S F Tang; T Y W Hon; C S Chan; K H Chan; J S C Ng; B J Zheng; W L Ng; R W M Lai; Y Guan; K Y Yuen
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

8.  Effects of a SARS-associated coronavirus vaccine in monkeys.

Authors:  Wentao Gao; Azaibi Tamin; Adam Soloff; Leonardo D'Aiuto; Edward Nwanegbo; Paul D Robbins; William J Bellini; Simon Barratt-Boyes; Andrea Gambotto
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

9.  Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003.

Authors:  N S Zhong; B J Zheng; Y M Li; Z H Xie; K H Chan; P H Li; S Y Tan; Q Chang; J P Xie; X Q Liu; J Xu; D X Li; K Y Yuen; Y Guan
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

10.  Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

Authors:  Alexander Bukreyev; Elaine W Lamirande; Ursula J Buchholz; Leatrice N Vogel; William R Elkins; Marisa St Claire; Brian R Murphy; Kanta Subbarao; Peter L Collins
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

View more
  26 in total

1.  Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.

Authors:  Wen-Hsiang Chen; Lanying Du; Shivali M Chag; Cuiqing Ma; Nancy Tricoche; Xinrong Tao; Christopher A Seid; Elissa M Hudspeth; Sara Lustigman; Chien-Te K Tseng; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Shibo Jiang
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

2.  Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate.

Authors:  Ileanet Ávalos; Thailin Lao; Elsa María Rodríguez; Yasser Zamora; Alianet Rodríguez; Ailyn Ramón; Gilda Lemos; Ania Cabrales; Monica Bequet-Romero; Dionne Casillas; Ivan Andújar; Luis Ariel Espinosa; Luis Javier González; Yanitza Alvarez; Yamila Carpio; Mario Pablo Estrada
Journal:  Vaccines (Basel)       Date:  2022-06-03

3.  Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.

Authors:  Lanying Du; Lei Jin; Guangyu Zhao; Shihui Sun; Junfeng Li; Hong Yu; Ye Li; Bo-Jian Zheng; Robert C Liddington; Yusen Zhou; Shibo Jiang
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

4.  Receptor-binding domain as a target for developing SARS vaccines.

Authors:  Xiaojie Zhu; Qi Liu; Lanying Du; Lu Lu; Shibo Jiang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

5.  Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.

Authors:  Chien-Te Tseng; Elena Sbrana; Naoko Iwata-Yoshikawa; Patrick C Newman; Tania Garron; Robert L Atmar; Clarence J Peters; Robert B Couch
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

6.  The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates.

Authors:  Jing Wang; Nancy Tricoche; Lanying Du; Meredith Hunter; Bin Zhan; Gaddam Goud; Elizabeth S Didier; Jing Liu; Lu Lu; Preston A Marx; Shibo Jiang; Sara Lustigman
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

Review 7.  Receptor-binding domain-based subunit vaccines against MERS-CoV.

Authors:  Naru Zhang; Jian Tang; Lu Lu; Shibo Jiang; Lanying Du
Journal:  Virus Res       Date:  2014-11-20       Impact factor: 3.303

8.  Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.

Authors:  Wen-Hsiang Chen; Shivali M Chag; Mohan V Poongavanam; Amadeo B Biter; Ebe A Ewere; Wanderson Rezende; Christopher A Seid; Elissa M Hudspeth; Jeroen Pollet; C Patrick McAtee; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez
Journal:  J Pharm Sci       Date:  2017-04-26       Impact factor: 3.534

9.  Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.

Authors:  Shibo Jiang; Maria Elena Bottazzi; Lanying Du; Sara Lustigman; Chien-Te Kent Tseng; Elena Curti; Kathryn Jones; Bin Zhan; Peter J Hotez
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

10.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.

Authors:  Cuiqing Ma; Lili Wang; Xinrong Tao; Naru Zhang; Yang Yang; Chien-Te K Tseng; Fang Li; Yusen Zhou; Shibo Jiang; Lanying Du
Journal:  Vaccine       Date:  2014-09-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.